JP2011514356A5 - - Google Patents

Download PDF

Info

Publication number
JP2011514356A5
JP2011514356A5 JP2010550648A JP2010550648A JP2011514356A5 JP 2011514356 A5 JP2011514356 A5 JP 2011514356A5 JP 2010550648 A JP2010550648 A JP 2010550648A JP 2010550648 A JP2010550648 A JP 2010550648A JP 2011514356 A5 JP2011514356 A5 JP 2011514356A5
Authority
JP
Japan
Prior art keywords
formulation
composition
salt
group
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010550648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011514356A (ja
JP5667885B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/003406 external-priority patent/WO2009113984A1/en
Publication of JP2011514356A publication Critical patent/JP2011514356A/ja
Publication of JP2011514356A5 publication Critical patent/JP2011514356A5/ja
Application granted granted Critical
Publication of JP5667885B2 publication Critical patent/JP5667885B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010550648A 2008-03-14 2008-03-14 化学的保護方法及び組成物 Active JP5667885B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/003406 WO2009113984A1 (en) 2008-03-14 2008-03-14 Chemoprotective methods and compositions

Publications (3)

Publication Number Publication Date
JP2011514356A JP2011514356A (ja) 2011-05-06
JP2011514356A5 true JP2011514356A5 (enExample) 2011-06-16
JP5667885B2 JP5667885B2 (ja) 2015-02-12

Family

ID=41065493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550648A Active JP5667885B2 (ja) 2008-03-14 2008-03-14 化学的保護方法及び組成物

Country Status (6)

Country Link
EP (1) EP2252246B1 (enExample)
JP (1) JP5667885B2 (enExample)
AU (1) AU2008352598B2 (enExample)
CA (1) CA2717915A1 (enExample)
ES (1) ES2476602T3 (enExample)
WO (1) WO2009113984A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984379C (en) 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity
WO2018229218A1 (en) * 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd25 adc
AU2019361856B2 (en) * 2018-10-19 2024-11-07 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
AU2020235823A1 (en) * 2019-03-08 2021-11-04 Lantern Pharma Inc. Method for treating female non-smokers with non-small cell lung cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7021A (en) * 1850-01-15 Substitute for the clevis
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6037336A (en) 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
JP2004523518A (ja) * 2001-01-19 2004-08-05 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド より効能が大きく副作用の少ない癌治療方法
US7176192B2 (en) * 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
WO2005051444A2 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
US20050256055A1 (en) * 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
WO2007070599A2 (en) * 2005-12-13 2007-06-21 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions

Similar Documents

Publication Publication Date Title
CN106860870B (zh) 抗肿瘤生物碱的联合治疗
JP2007534730A (ja) 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物
JP2014012721A (ja) ｍＴＯＲ阻害剤投与によるがん患者の治療
KR101848131B1 (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2015517523A5 (enExample)
CN101484443B (zh) 放射线治疗增强剂
WO2023114871A1 (en) Use of combination therapy for treating cancer
WO2010086964A1 (ja) がん治療のための併用療法
JP2009536956A (ja) 抗癌治療法
CN101107001A (zh) 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂
JP2015057409A (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
CA2648945A1 (en) Chemoprotective methods and compositions
WO2016014390A1 (en) Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
JP2011514356A5 (enExample)
WO2005049030A1 (en) Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
SK5032003A3 (en) Antitumor therapy comprising distamycin derivatives
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
US6822001B2 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
JP2009292837A (ja) より効能が大きく副作用の少ない癌治療方法
JP2011514355A5 (enExample)
ES2896051T3 (es) Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral
US20220395575A1 (en) Combination therapy with protein kinase b activation inhibitor to treat cancer
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体